|
summary: In this multicentre, randomised, placebo-controlled phase IIb trial, the effects of a new oral drug called fumarate were investigated in people with MS. A high dose of fumarate reduced MRI activity, was safe and had a similar effect on relapses to interferons. Further larger phase III trials are now needed to confirm these encouraging results.
authors: Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators
source: Lancet 2008 Oct 25;372(9648):1463-72
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
ACE
Interferon
Magnetic Resonance Imaging (MRI)
Multiple sclerosis
Placebo
Randomised
Relapse
Relapsing/remitting MS
Sclerosis
|
